Dyslipidemias
Conditions
Keywords
haemodialysis diabetes mellitus
Brief summary
* How dyslipidemia common among Diabetic and non- Diabetic Haemodialysis patients. * How differ dyslipidemia types among Diabetic and non- Diabetic in Haemodialysis patients. (Qualitative difference).
Detailed description
Diabetes mellitus (DM) is a metabolic disease , a consequence of defects in insulin action, secretion, or both, and there are complications associated with it, such as nephropathy, retinopathy, neuropathy, cardiovascular complications ,cerebrovascular and peripheral arterial disease. Diabetic nephropathy, which occurs in about one third of type 2 diabetic patients, is the most common factor leading to end-stage renal disease (ESRD) . A very common metabolic abnormality associated with diabetes is dyslipidemia, which is characterized by a spectrum of quantitative and qualitative changes in lipids and lipoproteinsSeveral previous studies have pursued linking blood glucose levels to serum lipid activities. The etiology of dyslipidemia appears to be centered on the increased large TAG-rich very low-density lipoprotein-cholesterol (VLDL-C) and its impaired clearance. American diabetic association (ADA) defines dyslipidemia as hypercholesterolemia ≥200 mg/dl of serum total cholesterol, hypertriglyceridemia ≥150 mg/dl of serum triglyceride, reduced high density lipoprotein cholesterol (HDL-C) \<40 mg/dl for men and \<50 mg/dl for women, elevated low density lipoprotein cholesterol (LDL-C) ≥70 mg/dl and high TC to HDL-C ratio of ≥4.5. Normal plasma lipids and lipoprotein metabolism is critical for cellular cholesterol homeostasis and protection against atherosclerosis, renal disease and other complication . A study found that people with high blood pressure and overweight or obesity have a higher risk of developing dyslipidemia ,Early detection and effective control of blood lipid levels can reduce the morbidity and mortality of CVD in patients with DM. Therefore, it is important to determine the factors associated with dyslipidemia.
Interventions
process of filtering the blood of a person whose kidneys are not working normally from uremic toxins
Sponsors
Study design
Eligibility
Inclusion criteria
* Patients aged between 18 and 60 years. * Patients undergoing regular conventional Haemodialysis for more than 6 months
Exclusion criteria
* Peritoneal Dialysis * Haemodiafilteration * Acute Kidney Injury * Nephrotic syndrome * Hypothyroidism * Familial hypertriglyceridemia. * Acute pancreatitis * Connective tissue disease. * Decompensated liver disease * Active malignancy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| dyslipidemia prevalence among Diabetic versus non- Diabetic Haemodialysis patients | baseline | haemodialysis patients for more than six months, and is with diabetes related to affect prevalance of dyslipidemia among these patients |